News about "Drug Development"

Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721

Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.

Drug Development | 09/07/2026 | By News Bureau

Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome

Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.

Drug Development | 06/07/2026 | By Akanki |  153

Lupin Secures EMA Approval for Expanded NaMuscla Pediatric Use

Lupin has received EMA approval to expand the pediatric indication of NaMuscla, including two new capsule strengths of 62 mg and 83 mg.

Drug Development | 03/07/2026 | By News Bureau |  322

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Drug Development | 23/06/2026 | By News Bureau |  311

Bayer Completes Acquisition of Perfuse Therapeutics

Bayer has completed the acquisition of Perfuse Therapeutics, strengthening its ophthalmology pipeline and expanding its portfolio of innovative eye disease treatments.

Drug Development | 19/06/2026 | By News Bureau

Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline

Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.

Drug Development | 07/05/2026 | By News Bureau

Alloy Therapeutics and IPI Partners to Advance Next-Gen Antibody Discovery

Alloy Therapeutics and IPI collaborate to develop advanced VHH libraries for faster, more efficient next-generation antibody discovery.

Drug Development | 06/05/2026 | By News Bureau |  120

AbbVie Provides US Regulatory Update on TrenibotE BLA

AbbVie gets US FDA Complete Response Letter (CRL) for TrenibotE BLA tied to manufacturing processes; no new clinical studies needed.

Drug Development | 24/04/2026 | By News Bureau |  107

Piramal Pharma Solutions Expands ADC Capabilities with Ajinomoto Bio-Pharma Services Pact

Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to accelerate ADC development and manufacturing, enabling access to AJICAP technology.

Drug Development | 20/04/2026 | By News Bureau |  130

NHS Speeds Up Clinical Trials, Accelerating Patient Access to New Treatments

The Government-backed reforms and Euro 137 million investment cut trial set-up times, strengthening the UK’s position as a global leader in clinical research and innovation.

Drug Development | 17/04/2026 | By News Bureau |  116